Decision Support Systems for HPV Vaccine

Providing families and clinicians with information to support decisions about starting and completing the human papillomavirus (HPV) vaccine series increases appropriate use of the vaccine, an AHRQ-funded study shows. The HPV vaccine is effective in preventing some types of cervical cancer and requires a total of three shots given over 6 months. The study evaluated the impact of family education and electronic alerts for clinicians on vaccination rates. Electronic alerts for clinicians were most likely to impact delivery of the first shot, while education and reminders for families were associated with the second and third vaccine shots. “The Implementation and Acceptability of an HPV Vaccination Decision Support System Directed at Both Clinicians and Families” appeared in the 2012 AMIA Annual Symposium Proceedings.

Go to: http://www.ncbi.nlm.nih.gov/pubmed/23650297

2013 Jun;131(6):1114-24. doi: 10.1542/peds.2012-3122. Epub 2013 May 6.

Effectiveness of Decision Support for Families, Clinicians, or Both on HPV Vaccine Receipt.

Fiks AG, Grundmeier RW, Mayne S, Song L, Feemster K, Karavite D, Hughes CC, Massey J, Keren R, Bell LM, Wasserman R, Localio AR.

Source

The Pediatric Research Consortium, The Children's Hospital of Philadelphia, 3535 Market Suite, Room 1546, Philadelphia, PA 19104. fiks@email.chop.edu.

Abstract

OBJECTIVE:

To improve human papillomavirus (HPV) vaccination rates, we studied the effectiveness of targeting automated decision support to families, clinicians, or both.

METHODS:

Twenty-two primary care practices were cluster-randomized to receive a 3-part clinician-focused intervention (education, electronic health record-based alerts, and audit and feedback) or none. Overall, 22 486 girls aged 11 to 17 years due for HPV vaccine dose 1, 2, or 3 were randomly assigned within each practice to receive family-focused decision support with educational telephone calls. Randomization established 4 groups: family-focused, clinician-focused, combined, and no intervention. We measured decision support effectiveness by final vaccination rates and time to vaccine receipt, standardized for covariates and limited to those having received the previous dose for HPV #2 and 3. The 1-year study began in May 2010.

RESULTS:

Final vaccination rates for HPV #1, 2, and 3 were 16%, 65%, and 63% among controls. The combined intervention increased vaccination rates by 9, 8, and 13 percentage points, respectively. The control group achieved 15% vaccination for HPV #1 and 50% vaccination for HPV #2 and 3 after 318, 178, and 215 days. The combined intervention significantly accelerated vaccination by 151, 68, and 93 days. The clinician-focused intervention was more effective than the family-focused intervention for HPV #1, but less effective for HPV #2 and 3.

CONCLUSIONS:

A clinician-focused intervention was most effective for initiating the HPV vaccination series, whereas a family-focused intervention promoted completion. Decision support directed at both clinicians and families most effectively promotes HPV vaccine series receipt.